Table III.5: Reported Provisions Related to Labeling and Testing of Compounded Drug Products, by Reporting State, as of January 1, 2016
State Compounded drug products are required to have labeling that indicates that the drug is a compounded drug Nonsterile compounded drugs are subject to random or routine sampling for potency and purity Sterile compounded drugs are subject to random or routine sampling for potency, purity, and sterility
Alabama No No No
Arizona - Yes Yes
Arkansas Yes No Yes
California Yes Yes Yes
Colorado Yes No Yes
Connecticut Yes No No
Delaware No No No
District of Columbia No No No
Florida Yes No No
Georgia Yes Yes Yes
Guam No No No
Hawaii Don't know Don't know Don't know
Idaho Yes Yes Yes
Illinois - Yes Yes
Iowa Yes Don't know Don't know
Kansas Yes No No
Kentucky No No No
Louisiana No No No
Maine - - -
Maryland - - -
Massachusetts Yes No Yes
Michigan Don't know Don't know Don't know
Minnesota No No No
Mississippi No No No
Missouri No No Yes
Montana Yes No No
Nebraska Yes No Yes
Nevada Yes Yes Yes
New Hampshire Yes Yes Yes
New Jersey Yes Yes Yes
New Mexico No No Yes
New York Yes No No
North Carolina No Yes Yes
North Dakota No Yes Yes
Ohio Yes Yes Yes
Oklahoma Yes Yes Yes
Oregon No Yes Yes
Pennsylvania No No No
Rhode Island No No Yes
South Carolina No No No
South Dakota No No No
Tennessee Yes Don't know Yes
Texas Yes No Yes
Utah Yes No Yes
Vermont Yes No No
Virginia Yes No No
Washington No Yes Yes
West Virginia - - -
Wisconsin No No No
Wyoming Yes No Yes

Source: GAO survey of state pharmacy regulatory bodies, survey question 15. | GAO-17-363SP
Note: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.